RBC Capital Maintains Outperform on CVS Health, Lowers Price Target to $91
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Ben Hendrix has maintained an 'Outperform' rating on CVS Health (NYSE:CVS), but lowered the price target from $102 to $91.
August 04, 2023 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has maintained an 'Outperform' rating on CVS Health, but lowered the price target from $102 to $91.
The news is directly about CVS Health. The 'Outperform' rating suggests that RBC Capital expects CVS to outperform the market, which is positive. However, the lowering of the price target could be seen as a negative signal, suggesting that RBC Capital expects a lower return from CVS than previously anticipated. This mixed signal is why the score is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100